The Thesis
News-sentiment is one of our more intuitive strategies: buy names showing positive recent news sentiment, exit when the tone turns negative. It trades a 24-name large-cap universe spanning tech (AAPL, MSFT, NVDA), financials (JPM, V, MA), healthcare (JNJ, PFE), and staples (KO, PG, WMT). The appeal is obvious — sentiment is a real, fast-moving driver of price. The hard part, as the numbers below show, is turning that intuition into a signal that fires often enough and reliably enough to matter.
Recent Activity
The defining feature of recent activity is how little of it there is. Across the scheduled runs from 30 October through 6 November, almost every session recorded 0 executed, 0 rejected — the signal simply did not trigger. The one exception was 3 November, when the strategy executed a single buy (21 shares of KO at $95.13). The late-October rebalance was busier, adding PFE (66 @ $29.92), NVDA (9 @ $213.49), and V (4 @ $410.29).
Meanwhile, total portfolio value has drifted down from roughly $9,987 at the start of November to $9,726 on 6 November, against a $10,000 starting line. Cash sits idle at $2,387.18. This is a strategy that is currently losing a little while doing very little.
Backtest and Validation
The headline backtest looks placid: +0.19% total return over 451 days, final equity $10,018.55, Sharpe 0.74, and a tiny 0.05% max drawdown on just $2 of fees. But that calm is an illusion created by inactivity — the backtest contains only 2 trades, and reported win rate is 0%.
Walk-forward validation is where the caution hardens into a warning. Validation failed. Of four folds, three produced zero trades and zero return; only fold 4 (Dec 2025–May 2026) actually traded, delivering the entire 0.19% return and a flattering 1.5 out-of-sample Sharpe. So one positive fold out of four, and the full-period result is really a single-window artifact. The probabilistic Sharpe ratio (0.923) looks encouraging, but the deflated Sharpe (0.551) — which accounts for the 6 trials run — is weak, and consistent with validation not passing.
Strengths and Risks
Strengths: the strategy is disciplined and cheap. It refuses to trade without a signal, keeps drawdown negligible, and has incurred trivial fees and zero FX cost. It will not blow up.
Risks: it barely participates. With only two trades across a 451-day backtest and three of four validation folds completely dormant, there is almost no statistical basis for confidence. The 0% win rate alongside a marginally positive return points to unrealized open positions carrying the result rather than a repeatable edge. Until the sentiment trigger fires more often — and survives a multi-fold test — news-sentiment should be read as an unproven candidate kept on a short leash, not a validated performer.